RxDoctor Payments Data

David Ginsberg, MD

Urology · Los Angeles, CANPI 1073534525

Payments from drug & device makers

$40,929in general payments, 2019–2025

Across 153 payments — averaging $267.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urovant Sciences Inc$13K
  • Medtronic$8K
  • Caldera Medical, Inc$7K
  • Sumitomo Pharma America, Inc.$6K
  • Laborie Medical Technologies Corp.$4K
  • Boston Scientific$1K
  • plus $3K from 14 others

What the payments were for

  • Consulting fees$10,25045%
  • Speaking & faculty fees$3,37515%
  • Grants$1211%
  • Travel & lodging$3712%
  • Food & beverage$8,56238%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,929 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$193,325
Medicare patients
651
Services billed
1,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron250$142,221
GemtesaVibegron39$25,031
Estradiol77$7,553
Methenamine Hippurate96$4,084
Tolterodine Tartrate ErTolterodine Tartrate29$3,752
Solifenacin Succinate68$2,435
Tamsulosin Hcl108$1,422
Oxybutynin Chloride ErOxybutynin Chloride50$1,279
Desmopressin Acetate16$623
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst47$400
Finasteride17$179
Sodium ChlorideSodium Chloride Irrig Solution19$106
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$36

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$78$142,221250 claims
Sumitomo Pharma America, Inc.Gemtesa$5,725$25,03139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →